Chengdu Shengnuo Biopharm Co., Ltd. (hereinafter referred to as“Shengnuo Biopharm”) is a wholly-owned subsidiary of Chengdu Shengnuo Biotechnology Co., Ltd. It was established in October, 2004 and is regarded as a "High-tech Enterprise Certified by Sichuan Province" and a "Sichuan Provincial Enterprise Technology Center". With a registered capital of 50 million yuan, it possesses over 50 key technologies for the large-scale production of peptides that have been marketed both domestically and internationally. It is a mature professional enterprise in China for the large-scale production of peptides and amino acid drugs, with a single batch output reaching the kilogram level and has passed the US FDA certification.

Chengdu Shengnuo Biopharm Co., Ltd. is a specialized, sophisticated, and innovative enterprise and a national high-tech enterprise specializing in the peptide field, which went public in 2021. We integrate R&D, production, and sales, with business covering peptide active pharmaceutical ingredients (APIs), cosmetic bioactive peptides, CDMO services, and peptide formulations. As a leading company in China's peptide API sector, we focus on the development, production, and technical services of peptide drugs, possessing full industrial chain capabilities from drug discovery to commercial manufacturing.